Royal Bank Of Canada Durect Corp Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $5.9 $23 - $318	54 New	54 $0
Q2 2022 Aug 15, 2022	SELL	$0.38 - $0.64 $5,282 - $8,896	-13,900 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.55 - $0.98 $20,841 - $37,135	-37,893 Reduced 73.16%	13,900 $9,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $23,875 - $34,751	26,528 Added 105.0%	51,793 $52,000
Q3 2021 Nov 15, 2021	BUY	$1.21 - $1.61 $4,297 - $5,718	3,552 Added 16.36%	25,265 $32,000
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $34,740 - $43,860	21,713 New	21,713 $35,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $189M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.